Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.74 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 9/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12930218 | 0.87 | TRPA1 (0.57) | TRPA1ACHECDC25AHSP90AA1ALDH1A1 | |
| SCHEMBL12930177 | 0.85 | TRPA1 (0.61) | TRPA1CDC25A | |
| SCHEMBL1061089 | 0.85 | TRPA1 (1.00) | TRPA1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL1061091 | 0.85 | TRPA1 (1.00) | TRPA1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL12930285 | 0.84 | TRPA1 (0.69) | TRPA1CDC25A | |
| SCHEMBL1061470 | 0.84 | TRPA1 (0.72) | TRPA1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL1061471 | 0.84 | TRPA1 (0.72) | TRPA1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL13652120 | 0.83 | TRPA1 (0.68) | TRPA1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL29260669 | 0.81 | CASP1 (0.52) | TRPA1ACHEHSP90AA1ALDH1A1ALDH2 | |
| SCHEMBL29260666 | 0.81 | CASP1 (0.52) | TRPA1ACHEHSP90AA1ALDH1A1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009379-A1 | INDOLINONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009379-A1 | INDOLINONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2261206-A1 | INDOLINONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009123080-A1 | INDOLINONE COMPOUND | アステラス製薬株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009379-A1 | INDOLINONE COMPOUND | TRPA1, TRPV1, TRPV6 | TRPA1 1/4885ACHE 209/4885CDC25A 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.